4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMTFree Report) in a research report report published on Friday, Benzinga reports. They currently have a $36.00 price target on the stock.

A number of other brokerages have also recently weighed in on FDMT. Royal Bank of Canada lifted their price target on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the company an outperform rating in a research report on Monday, April 15th. BMO Capital Markets dropped their target price on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an outperform rating for the company in a report on Monday, April 1st. Barclays started coverage on 4D Molecular Therapeutics in a research note on Monday, April 15th. They set an overweight rating on the stock. Finally, Jefferies Financial Group lifted their price objective on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a buy rating in a research note on Monday, April 1st. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of Buy and an average price target of $44.22.

View Our Latest Analysis on 4D Molecular Therapeutics

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $22.72 on Friday. 4D Molecular Therapeutics has a one year low of $9.44 and a one year high of $36.25. The firm has a market cap of $1.17 billion, a PE ratio of -9.31 and a beta of 2.89. The firm’s 50 day moving average price is $25.75 and its 200-day moving average price is $23.66.

4D Molecular Therapeutics (NASDAQ:FDMTGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.07. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.44 million. 4D Molecular Therapeutics had a negative return on equity of 26.75% and a negative net margin of 436.30%. Equities research analysts predict that 4D Molecular Therapeutics will post -2.98 EPS for the current fiscal year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 5,833 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $35.04, for a total transaction of $204,388.32. Following the completion of the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at $60,864.48. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 19,236 shares of company stock valued at $607,796 in the last quarter. Corporate insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trexquant Investment LP purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth $566,000. Aigen Investment Management LP purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter worth about $216,000. Wellington Management Group LLP boosted its position in shares of 4D Molecular Therapeutics by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock worth $2,199,000 after acquiring an additional 3,638 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of 4D Molecular Therapeutics by 359.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after acquiring an additional 3,873 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of 4D Molecular Therapeutics by 3.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 268,638 shares of the company’s stock worth $5,443,000 after acquiring an additional 10,130 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

Read More

Analyst Recommendations for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.